Amyloidosis
133
30
35
61
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Published Results
20 trials with published results (15%)
Research Maturity
61 completed trials (46% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.8%
9 terminated out of 133 trials
87.1%
+0.6% vs benchmark
8%
11 trials in Phase 3/4
33%
20 of 61 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 61 completed trials
Clinical Trials (133)
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
HIBA-Institutional Registry of Amyloidosis
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Dietary Reporting In The Amyloidoses
Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia
Prevalence and Significance of ATTR Aortic Valve Amyloidosis in Degenerative Aortic Stenosis
Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial
NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis
A Phase 3 Study of NTLA-2001 in ATTRv-PN
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
Impact of a Cardiac Rehabilitation Program on Patients With Cardiac Amyloidosis
Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
BE.Amycon Biobank & Data Registry UZ Leuven